HLA associations in narcolepsy type 1 persist after the 2009 H1N1 pandemic

Citation for published version (APA):

Document license:
CC BY-NC-ND

DOI:
10.1016/j.jneuroim.2020.577210

Document status and date:
Published: 15/05/2020

Document Version:
Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:
- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.tue.nl/taverne

Take down policy
If you believe that this document breaches copyright please contact us at:
openaccess@tue.nl
providing details and we will investigate your claim.

Download date: 14. Jun. 2020
HLA associations in narcolepsy type 1 persist after the 2009 H1N1 pandemic

Mink Schinkelshoek a,b, Rolf Fronczek a,b, Willem Verduijn c, Geert Haasnoot c, Sebastiaan Overeem d,e, Claire Donjacour f, Astrid van der Heide g, Dave Roelen c, Frans Claas c, Gert Jan Lammers a,b

a Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300, RC, Leiden, The Netherlands
b Sleep Wake Centre, Stichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, 2103, SW, Heemstede, The Netherlands
c Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, PO Box 9600, 2300, RC, Leiden, The Netherlands
d Department of Electrical Engineering, Eindhoven University of Technology, PO Box 513, 5600, MB, Eindhoven, The Netherlands
e Sleep Wake Centre, Stichting Epilepsie Instellingen Nederland (SEIN), Dokter Denekampweg 20, 8025, BV, Zwolle, The Netherlands
f Sleep Medicine Center Kempenhaeghe, PO Box 61, 5590, AB, Heeze, The Netherlands
g Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, PO Box 9600, 2300, RC, Leiden, The Netherlands

ARTICLE INFO

Keywords:
Narcolepsy
H1N1
HLA
Hypocretin
Auto-immune disease

ABSTRACT

We aimed to compare HLA-DQB1-associations in narcolepsy type 1 (NT1) patients with disease onset before and after the 2009 H1N1 pandemic in a large Dutch cohort. 525 NT1 patients and 1272 HLA-DQB1*06:02-positive healthy controls were included. Because of the discussion that has arisen on the existence of sporadic and post-H1N1 NT1, HLA-DQB1-associations in pre- and post-H1N1 NT1 patients were compared. The associations between HLA-DQB1 alleles and NT1 were not significantly different between pre- and post-H1N1 NT1 patients. Both HLA-DQB1-associations with pre- and post-H1N1 NT1 reported in recent smaller studies were replicated. Our findings combine the results of studies in pre- and post-H1N1 NT1 and argue against considering post-H1N1 NT1 as a different entity.

1. Introduction

Narcolepsy type 1 (NT1) is a rare disorder of the regulation of sleep and wakefulness with an incidence of 1 per 100,000 person years and prevalence ranging between 20 and 50 per 100,000 individuals (Wijnans et al., 2013). NT1 is characterised by five core symptoms: excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis and disturbed nocturnal sleep. These symptoms arise as a result of the presumed destruction of over 90% of hypocretin (Hcrt)-producing neurons in the lateral hypothalamus hypothesized as being caused by an auto-immune response (Bassetti et al., 2019; Kornum et al., 2017).

95% of NT1 patients carry the HLA-DQA1*01:02 / DQB1*06:02 haplotype encoding HLA-DQB1*06:02, an HLA-class II molecule expressed on antigen presenting cells (Tafi et al., 2014). HLA-DQB1*06:02 is also present in about 20% of the general European population. As a result, HLA-DQB1*06:02 has been considered as a genetic factor necessary but not sufficient for development of NT1. Apart from the well-known association with HLA-DQB1*06:02, there are positive and negative associations between other HLA-DQB1 alleles and NT1: the frequency of HLA-DQB1*03:01 (HLA-DQ7) was found to be increased, whereas HLA-DQB1*02:01 (HLA-DQ2), HLA-DQB1*05:01, HLA-DQB1*06:01, HLA-DQB1*06:03 and HLA-DQB1*06:09 were decreased in NT1 patients compared with healthy controls (Hong et al., 2007; Ollila et al., 2015; Tafti et al., 2014).

An increase in the incidence of NT1 has been observed in several European countries since the 2009 influenza A(H1N1) pdm09 pandemic, and the subsequent vaccination campaign (Dauvilliers et al., 2013; Feltelius et al., 2015; Lind et al., 2014; Partinen et al., 2012). Recent studies have identified autoreactive T cells against hypocretin peptides (Latorre et al., 2018; Pedersen et al., 2019), but their reactivity was not HLA-DQB1*06:02 restricted. Reports on T cells recognizing both H1N1 and hypocretin peptides show conflicting results (Luo et al., 2018; Schinkelshoek et al., 2019), with detected T cell cross-reactivity

Abbreviations: H1N1, 2009 pandemic (H1N1)pdm09 influenza A strain; Hcrt, hypocretin; HLA-DQ2, Human leucocyte antigen molecule encoded by the HLA-DQB1*02:01 allele; HLA-DQ4, Human leucocyte antigen molecule encoded by the HLA-DQB1*04:01 allele; HLA-DQ7, Human leucocyte antigen molecule encoded by the HLA-DQB1*03:01 or 03:04 allele; HLA-DQ8, Human leucocyte antigen molecule encoded by the HLA-DQB1*03:02 or 03:05 allele; HLA-DQ9, Human leucocyte antigen molecule encoded by the HLA-DQB1*03:03 allele; ICSD-2/3, International Classification of Sleep Disorders, 2nd or 3rd edition; NT1, narcolepsy type 1

E-mail address: M.S.Schinkelshoek@lumc.nl (M. Schinkelshoek).

https://doi.org/10.1016/j.jneuroim.2020.577210
Received 4 December 2019; Received in revised form 2 March 2020; Accepted 3 March 2020
0165-5728/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
in the first study not being replicated in the second.

Following these epidemiological and laboratory reports, a discussion on the existence of a post-H1N1 NT1 variant has arisen, with specifically Scandinavian countries making the distinction between sporadic and post-H1N1 NT1. Several recent Scandinavian studies report HLA-DQ haplotypes associated specifically with post-H1N1 NT1 (HLA-DQ2, HLA-DQ7) (Juvodden et al., 2019; Lind et al., 2019). These reports started a discussion about whether different immunological mechanisms may be involved in post-H1N1 NT1.

Since these studies are small and only address HLA-DQB1-associations in a cohort of post-H1N1 NT1 patients and a healthy control population, our aim is to compare HLA-DQB1-associations in NT1 patients with disease onset before and after the 2009 H1N1 pandemic in a large Dutch cohort to assess whether differences can be seen which would test the hypothesis that sporadic and post-H1N1 NT1 should be regarded as separate entities based on different immunological mechanisms leading to the disease.

2. Materials and methods

2.1. Participants

We included all NT1 patients of European ancestry who, between 2005 and 2019, were HLA-genotyped for clinical care in the laboratory of the Leiden University Medical Center. Patients came from the sleep clinic of the Department of Neurology, Leiden University Medical Center, the Sleep-Wake Centre of Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede and Zwolle, and the Sleep Centre of Kempenhaeghe, Heeze. All patients were diagnosed with either narcolepsy with cataplexy or NT1 according to the International Classification of Sleep Disorders (ICSD-2 or ICSD-3; (ICSD, 2005, 2014)). Age at symptom onset was assessed in all patients to separate those with symptom onset in childhood (< 16 years at symptom onset) or adulthood, and we also noted whether the symptoms of NT1 started before or after the 2009 H1N1 pandemic to be able to compare HLA-DQB1-associations before and after the H1N1 pandemic. We also included a cohort of HLA-DQB1*06:02 positive non-related healthy individuals from a panel of randomly selected Dutch individuals (van Rooijen et al., 2012) to be able to assess HLA associations in NT1.

2.2. HLA typing

HLA genotyping for HLA-DR and HLA-DQ was performed with a reversed approach of the PCR-sequence-specific oligonucleotide probe technique previously described (Verduyn et al., 1993). If a rare DRB1-DQB1 was found, typing results were confirmed by PCR-SBT, using the SBT Excellerator HLA-DRB and -DQB kit (Genome Diagnostics, Utrecht, The Netherlands).

2.3. Statistical analysis

Pearson’s chi-square tests were used for comparisons. Odds ratios and corresponding 95% confidence intervals (CI) were calculated using Cochran-Mantel-Haenszel tests (Cochran, 1954; Mantel, 1963; Mantel and Haenszel, 1959). We compared the frequency of HLA-DQB1 alleles between NT1 patients and healthy controls who were HLA-DQB1*06:02 positive. We also compared the frequency of HLA-DQB1 alleles between NT1 patients with disease onset before and after the 2009 H1N1 pandemic. As the increase in NT1 incidence was reported predominantly in children with NT1, we assessed whether onset during childhood was associated with a change in HLA-DQB1-associations after the H1N1 pandemic.

Since one of our aims was specifically to replicate the results of other studies describing HLA-DQB1-associations in post-H1N1 NT1 patients, for these specific analyses corrections for multiple comparisons were not performed. For all other analyses, p-values were corrected for multiple comparisons according to the Šidák-Holm method (Šidák, 1967). Differences with p-values below 0.05 were deemed significant. All analyses were conducted using the IBM SPSS Statistics 25 software package. It must be noted that due to a high degree of linkage disequilibrium in the HLA complex, the tested alleles and loci are not independent.

3. Results

3.1. Participant characteristics

We included 525 NT1 patients (128 post-H1N1) and 1272 HLA-DQB1*06:02-positive controls. Participant characteristics are shown in Table 1. Notably, all but two NT1 patients were DQB1*06:02 positive. 158 patients had undergone a lumbar puncture for Hcrt-1 measurement; over 95% had Hcrt-1 values in the cerebrospinal fluid that were below the cut-off value of 110 pg/mL; all had Hcrt-1 values below 200 pg/mL.

3.2. The frequency of HLA-DQB1*06:02 homozygosity is unchanged between pre- and post-H1N1 NT1 patients

The important role of HLA-DQB1*06:02 in NT1 is demonstrated by its presence in almost all pre- and post-H1N1 NT1 patients (396/397 patients vs. 127/128 patients). Homozygosity for HLA-DQB1*06:02 is associated with NT1 with an odds ratio of 2.5 (7.2% in the healthy population, 16.2% in NT1 patients; Table 2). Furthermore, the percentage of NT1 patients homozygous for HLA-DQB1*06:02 is unchanged between pre- and post-H1N1 NT1 patients with 16.4% in pre-H1N1 NT1 patients and 15.6% in post-H1N1 NT1 patients (p = .79; Table 3).

3.3. Multiple HLA-DQ alleles other than HLA-DQB1*06:02 are associated with NT1

In addition to the association between HLA-DQB1*06:02 and NT1, Table 2 gives an overview of other HLA-DQ alleles and their association with NT1. HLA-DQ2, HLA-DQB1*05:01 and HLA-DQB1*06:03 are negatively associated with NT1, while HLA-DQ7 and HLA-DQB1*05:02 are more frequently found in NT1 patients than in healthy controls (Fig. 1).

3.4. No differences in HLA-DQB1 alleles in trans with HLA-DQB1*06:02 between pre- and post-H1N1 NT1 patients

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Narcolepsy type 1 patient characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-H1N1</td>
</tr>
<tr>
<td>N</td>
<td>397</td>
</tr>
<tr>
<td>Males</td>
<td>46%</td>
</tr>
<tr>
<td>Age at disease onset (years)</td>
<td>19 (3-67)</td>
</tr>
<tr>
<td>Disease onset during childhood (&lt; 16 years)</td>
<td>31%</td>
</tr>
<tr>
<td>Hcrt-1 &lt; 110 pg/mL</td>
<td>110/114 (97%)</td>
</tr>
<tr>
<td>Hcrt-1 &lt; 200 pg/mL</td>
<td>114/114 (100%)</td>
</tr>
<tr>
<td>HLA- DQB1*06:02 positive (n)</td>
<td>396/397</td>
</tr>
<tr>
<td>H1N1 vaccination (n)</td>
<td>NA</td>
</tr>
<tr>
<td>Proven H1N1 infection (n)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Data on age at disease onset are shown as median and range. Data are shown as a percentage of patients in which data was available. H1N1 = H1N1 influenza pandemic in 2009; Hcrt-1 = hypocretin-1; HLA-DQB1*06:02 = human leucocyte antigen molecule encoded by the HLA-DQB1*06:02 allele; NA = not applicable.
and post-H1N1 NT1 patients separately in Table 3. For all alleles in common odds ratio; pc-value = corrected p-value.

Table 2

<table>
<thead>
<tr>
<th>Pre-H1N1</th>
<th>Post-H1N1</th>
<th>OR</th>
<th>95% CI</th>
<th>p-value</th>
<th>pc-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>397</td>
<td>128</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>DQ2</td>
<td>62 (15.6%)</td>
<td>20 (15.4%)</td>
<td>0.98</td>
<td>0.57-1.7</td>
<td>0.949</td>
</tr>
<tr>
<td>DQ4</td>
<td>18 (4.5%)</td>
<td>6 (4.6%)</td>
<td>1.0</td>
<td>0.40-2.6</td>
<td>0.969</td>
</tr>
<tr>
<td>DQ7</td>
<td>95 (23.9%)</td>
<td>35 (27.3%)</td>
<td>1.2</td>
<td>0.76-1.9</td>
<td>0.436</td>
</tr>
<tr>
<td>DQ8</td>
<td>41 (10.3%)</td>
<td>15 (11.5%)</td>
<td>1.1</td>
<td>0.60-2.1</td>
<td>0.697</td>
</tr>
<tr>
<td>DQ9</td>
<td>19 (4.8%)</td>
<td>2 (1.5%)</td>
<td>0.31</td>
<td>0.07-1.4</td>
<td>0.100</td>
</tr>
<tr>
<td>DQB1*0101</td>
<td>29 (7.3%)</td>
<td>6 (4.6%)</td>
<td>0.61</td>
<td>0.25-1.5</td>
<td>0.285</td>
</tr>
<tr>
<td>DQB1*0201</td>
<td>4 (1.0%)</td>
<td>0 (0%)</td>
<td>NA</td>
<td>NA</td>
<td>0.417</td>
</tr>
<tr>
<td>DQB1*0202</td>
<td>12 (3.0%)</td>
<td>6 (4.7%)</td>
<td>1.6</td>
<td>0.58-4.3</td>
<td>0.368</td>
</tr>
<tr>
<td>DQB1*0601</td>
<td>0 (0.5%)</td>
<td>0 (0%)</td>
<td>NA</td>
<td>NA</td>
<td>0.520</td>
</tr>
<tr>
<td>DQB1*0602</td>
<td>65 (16.4%)</td>
<td>20 (15.4%)</td>
<td>0.93</td>
<td>0.54-1.6</td>
<td>0.790</td>
</tr>
<tr>
<td>DQB1*0603</td>
<td>5 (1.3%)</td>
<td>1 (0.8%)</td>
<td>0.61</td>
<td>0.07-7.3</td>
<td>0.647</td>
</tr>
<tr>
<td>DQB1*0604</td>
<td>42 (10.7%)</td>
<td>13 (10.0%)</td>
<td>1.5</td>
<td>0.74-2.9</td>
<td>0.276</td>
</tr>
<tr>
<td>DQB1*0609</td>
<td>3 (0.8%)</td>
<td>0 (0%)</td>
<td>NA</td>
<td>NA</td>
<td>0.520</td>
</tr>
</tbody>
</table>

H1N1 = 2009 pandemic (H1N1)pdm09 influenza A strain; HLA-DQB1*0401/0402/0501/0503 are presented in different allelic combinations. All p-values are derived from Pearson Chi-Square tests. Pc-values are calculated using Mantel-Haenszel common odds ratio; pc-value = corrected p-value.

and post-H1N1 NT1 patients separately in Table 3. For all alleles in common odds ratio; pc-value = corrected p-value.

Table 3

<table>
<thead>
<tr>
<th>Allele</th>
<th>Pre-H1N1</th>
<th>Post-H1N1</th>
<th>OR</th>
<th>95% CI</th>
<th>p-value</th>
<th>pc-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DQB1*0201</td>
<td>315</td>
<td>82 (15.6%)</td>
<td>0.56</td>
<td>0.43-0.73</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>DQB1*0203</td>
<td>37 (2.9%)</td>
<td>24 (4.6%)</td>
<td>1.6</td>
<td>0.94-2.7</td>
<td>0.079</td>
<td>0.658</td>
</tr>
<tr>
<td>DQB1*0302</td>
<td>216</td>
<td>130 (24.8%)</td>
<td>1.6</td>
<td>1.3-2.1</td>
<td>&lt; 0.001</td>
<td>0.002</td>
</tr>
<tr>
<td>DQB1*0303</td>
<td>137</td>
<td>56 (10.6%)</td>
<td>0.99</td>
<td>0.72-1.4</td>
<td>0.97</td>
<td>1</td>
</tr>
<tr>
<td>DQB1*0401</td>
<td>67 (5.3%)</td>
<td>21 (4.0%)</td>
<td>0.75</td>
<td>0.45-1.2</td>
<td>0.251</td>
<td>0.977</td>
</tr>
<tr>
<td>DQB1*0501</td>
<td>187</td>
<td>35 (6.6%)</td>
<td>0.42</td>
<td>0.28-0.60</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>DQB1*0601</td>
<td>21 (1.6%)</td>
<td>22 (4.2%)</td>
<td>2.7</td>
<td>1.5-5.0</td>
<td>0.001</td>
<td>0.011</td>
</tr>
<tr>
<td>DQB1*0603</td>
<td>36 (2.8%)</td>
<td>18 (3.4%)</td>
<td>1.2</td>
<td>0.69-2.2</td>
<td>0.499</td>
<td>1</td>
</tr>
<tr>
<td>DQB1*0604</td>
<td>18 (0.4%)</td>
<td>2 (0.4%)</td>
<td>0.97</td>
<td>0.19-5.0</td>
<td>0.966</td>
<td>1</td>
</tr>
<tr>
<td>DQB1*0605</td>
<td>28 (7.1%)</td>
<td>13 (10.0%)</td>
<td>1.5</td>
<td>1.0-2.4</td>
<td>0.024</td>
<td>0.567</td>
</tr>
<tr>
<td>DQB1*0609</td>
<td>11 (0.9%)</td>
<td>3 (0.6%)</td>
<td>0.66</td>
<td>0.18-2.4</td>
<td>0.516</td>
<td>1</td>
</tr>
<tr>
<td>NT1 vs NA</td>
<td>1.2</td>
<td>0.251</td>
<td>0.977</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR 95% CI p-value pc-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

One of the limitations in our study is that we have not been able to distinguish between post-H1N1 NT1 patients and healthy controls who encountered the H1N1 virus or were vaccinated. We have data on this group is reported in Supplementary Table 1. Given the fact that the H1N1 vaccination coverage in the Netherlands was 30% for the general population and 74% for children (Mereckiene et al., 2012), it is likely that at least a significant percentage of patients with symptom onset after 2009 encountered the H1N1 virus or were vaccinated against H1N1 during the vaccination campaign. Another factor to consider is the hypothesized post-vaccination risk window, that is defined as a period of two years after the H1N1 vaccination campaign in which the risk of developing narcolepsy type 1 was increased (Sarkanen et al., 2018). Only a small group of participants in the current study were diagnosed in 2010 and 2011, which makes a separate analysis on this group unfeasible. Data on this group is reported in Supplementary Table 2.

Our findings bridge the findings of studies in sporadic and post-H1N1. In addition to replicating HLA-associations reported in studies focusing on either sporadic NT1 or post-H1N1 NT1 patients, we show that these HLA-DQB1-associations can be found in both groups. Focusing on performing research on the autoimmune hypothesis of NT1 in NT1 patients shortly after symptom onset seems more promising than directing further research to the difference between sporadic and post-H1N1 NT1.

5. Conclusions

No differences in HLA-associations were found between NT1 patients with symptom onset before and those with symptom onset after...
(caption on next page)
the 2009 H1N1 pandemic. The positive association of HLA-DQ7 and negative associations of HLA-DQ2, HLA-DQB1*05:01 and DQB1*06:03 with both pre- and post-H1N1 described in other smaller studies were confirmed in this large Dutch cohort. These results therefore argue against considering sporadic and post-H1N1 NT1 to be separate entities.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jneuroim.2020.577210.

Declaration of Competing Interest

The authors confirm no conflict of interest to disclose.

Acknowledgements

We thank Pauline Amesz for drawing blood samples from most NT1 patients participating in this study, and Petra van Mierlo for managing the Kempenhaeghe biosamples. We thank Frits Koning, Gail Bell and Ley Sander for carefully assessing the manuscript.

References


Jalava, J., 2011. Detection of human leukocyte antigen molecule encoded by the HLA-DQB1*02:01-/DQB1*04:01/DQB1*03:01 or -/DQB1*03:03 allele; NT1 = narcolepsy type 1; * = p < .05, ** = p < .01, *** = p < .001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)